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Abstract The vascular endothelial growth factor (VEGF)
signaling pathway appears to be the dominant pathway
involved in tumor angiogenesis, providing a rationale for
targeting the VEGF receptors (VEGFR-1, -2, and -3) in the
treatment of cancers. In particular, VEGF signaling is
thought to be important in renal cell carcinoma (RCC)
because of the deregulation of the pathway through nearly
uniform loss of the von Hippel Lindau protein. The tyrosine
kinase inhibitors (TKIs) sorafenib, sunitinib, and pazopanib
are approved by the US Food and Drug Administration for
the treatment of advanced RCC; however, these multi-
targeted agents inhibit a wide range of kinase targets in
addition to the VEGFRs, resulting in a range of adverse
effects unrelated to efficient VEGF blockade. This article
reviews recent advances in the development of the second-
generation VEGFR TKIs, including the more selective
VEGFR TKIs tivozanib and axitinib, and focuses on the
potential benefits of novel inhibitors with improved
potency and selectivity.
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Introduction
Angiogenesis, the formation of new capillary blood
vessels, is fundamental to normal development and critical
for physiological processes in adults, such as reproduction
and wound healing. Angiogenesis is also associated with
pathologic conditions, such as rheumatoid arthritis, age-
related macular degeneration, and diabetic retinopathy,
and is also a crucial component of tumor growth and
metastasis [1]. As a nascent tumor grows, the cell mass
limits diffusion of oxygen, creating hypoxia, which in turn
activates the hypoxia-inducible factor (HIF) transcription
factors and thereby upregulates expression of the vascular
endothelial growth factor (VEGF) family of proteins.
When combined with appropriate proteolytic factors in
the microenvironment, the VEGFs enable the recruitment
and proliferation of nearby vessel structures to initiate and
sustain tumor neovasculature [2]. Evidence suggests that
acquisition of a blood supply is a rate-limiting step in the
establishment of solid tumors. Thus, inhibition of angio-
genesis has emerged as an important antitumor strategy for
solid tumors [3].
While a number of angiogenesis inducers have been
identified [1], the VEGF signaling pathway appears to be
the dominant pathway involved in tumor angiogenesis [3].
The VEGF family consists of five structurally related
proteins (VEGF-A, VEGF-B, VEGF-C, VEGF-D, and
placental growth factor [PLGF]), and signaling through
this pathway is mediated by the binding of these growth
factors to three receptors (VEGF receptor [VEGFR]-1,
VEGFR-2, and VEGFR-3). The ligands bind each receptor
with distinct but overlapping specificity as well as distinct
biological function, together acting to affect proliferation,
migration, and morphogenesis of endothelial cells to form
functional vasculature [4￿, 5, 6, 7].
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many different tumor types, advances in our understanding
of tumor cell biology have indicated a particularly strong
rationale for blocking VEGF as a treatment strategy in clear
cell renal cell carcinoma (RCC). Functional defects in the
von Hippel Lindau gene (VHL), which is a negative
regulator of HIF1 and HIF2 and thus a tumor suppressor,
are present in over 90% of clear cell RCC tumors [8]. VHL
inactivation results in the stabilization of HIFs, particularly
HIF2 [9, 10], and upregulation of the expression of a large
set of hypoxia-induced genes, including VEGF-A and
VEGF-C [8].
Therapeutic inhibition of the VEGF pathway may be
achieved via monoclonal antibodies or receptor traps
targeted to the various VEGF ligands (eg, bevacizumab
binding to VEGF-A, TB-403 binding to PLGF, aflibercept
binding to VEGFs), antibodies targeting the extracellular
domain of various VEGFRs (IMC-1C11 binding to
VEGFR-2), or via intracellular inhibition of VEGF signal-
ing through use of small-molecule tyrosine kinase inhibitors
(TKIs) that target the intracellular kinase domains of the
three VEGFRs [11]. This article reviews recent advances in
the development of second-generation VEGFR TKIs,
focusing on the potential benefits of novel inhibitors with
improved potency and selectivity.
Approved TKIs with Anti-VEGFR Activity
Over the past 4 years, three oral multitargeted TKIs,
sorafenib [12￿￿], sunitinib [13￿￿, 14], and pazopanib
[15￿￿], have been approved by the US Food and Drug
Administration (FDA) and the European Medicines
Agency for the treatment of advanced RCC. In addition
to the VEGFR tyrosine kinases, these agents potently
inhibit a wide range of tyrosine kinases and other targets
(such as platelet-derived growth factor receptor [PDGFR],
stem cell factor receptor [c-kit], FMS-like tyrosine kinase-3
[Flt3], rearranged during transfection [RET], colony-
stimulating factor 1 receptor [CSF1R], c-Raf, and Raf
homolog B1 [B-Raf]), which disrupt multiple signaling
pathways [12￿￿, 13￿￿, 14, 15￿￿, 16]. This lack of specificity
for the VEGFRs is manifested in the occurrence of several
toxicities that are unrelated to blockage of the VEGF
pathway, often termed “off-target” effects of multitargeted
TKIs. These toxicities have not been observed with the
monoclonal antibody bevacizumab, which is a selective
VEGF pathway inhibitor available for human use.
A phase 3 randomized study [13￿￿] comparing oral
sunitinib (50 mg once daily for 4 weeks, followed by
2 weeks without treatment) with subcutaneously adminis-
tered interferon (IFN)-α (9 million units 3 times weekly) as
first-line treatment in 750 patients with metastatic RCC
showed significant improvement in median progression-free
survival (PFS; 11 months vs 5 months, respectively; P<
0.001) and objective response rate (ORR; 31% vs 6%,
respectively; P<0.001) with sunitinib. While IFN-α was
associated with a higher incidence of grade 3 or 4 treatment-
related fatigue (12% vs 7% with sunitinib; P<0.05),
sunitinib was associated with a higher incidence of grade 3
diarrhea (5% vs 0%), vomiting (4% vs 1%), hypertension
(8% vs 1%), and hand-foot syndrome (5% vs 0%; P<0.05
for all comparisons). Sunitinib was also associated with a
higher incidence of grade 3 or 4 neutropenia (12% vs 7%,
respectively, including two cases of febrile neutropenia with
sunitinib) and thrombocytopenia (8% vs 0%; P<0.05 for all
comparisons). A total of 38% of patients in the sunitinib
group required a dose reduction, and 32% required a dose
interruption.
The pivotal phase 3, randomized, placebo-controlled
study [12￿￿] of sorafenib (TARGET) enrolled 903 patients
with advanced clear cell RCC that was resistant to therapy
with cytokines. Treatment with oral sorafenib 400 mg
twice daily significantly prolonged PFS (5.5 months)
compared with placebo (2.8 months; P<0.01); overall
survival (OS) was not significantly different between the
treatment groups. Partial responses were reported for 10%
of sorafenib-treated patients compared with 2% in the
placebo group (P<0.001). The most common grade 3 or 4
adverse events with sorafenib included hand-foot skin
reactions (6%), fatigue (5%), dyspnea (4%), and diarrhea
(2%); grade 3 or 4 hypertension and cardiac ischemia were
rare serious adverse events occurring more often with
sorafenib (4% and 3%, respectively) than with placebo
(<1% for both).
The activity of pazopanib was assessed in a randomized,
placebo-controlled, phase 3 study involving 435 patients
with locally advanced or metastatic RCC (46% of whom
were previously treated with cytokines) [15￿￿]. Median PFS
was significantly longer with pazopanib compared with
placebo in the overall study population (9.2 months vs
4.2 months; P<0.0001), as well as in the treatment-naive
(11.1 months vs 2.8 months; P<0.0001) and cytokine-
pretreated subpopulations (7.4 months vs 4.2 months; P<
0.001). ORR was also significantly greater with pazopanib
(30%) compared with placebo (3%; P<0.001). The most
common grade 3 and 4 adverse events associated with
pazopanib included diarrhea (4%), hypertension (4%),
lymphocytopenia (4%), and asthenia (3%). Abnormalities
in hepatic function were more frequent in the pazopanib
arm (alanine transaminase ≥3 times the upper limit of
normal in 18% of patients), and were associated with two
treatment-related deaths. In an expert review at the FDA
Oncology Drug Advisory Committee meeting, hepatotox-
icity with pazopanib was felt to be similar to that seen with
sunitinib during their phase 3 trial [17].
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Although multitargeted TKIs have demonstrated anti-
tumor activity, they are associated with a variety of
“off-VEGF target” effects related to their nonspecific
nature [16]. For example, hand-foot skin reactions,
fatigue, stomatitis, diarrhea, hair color changes, myelo-
suppression, and thyroid dysfunction are commonly
associated with treatment with multitargeted TKIs. Low
potency of currently available TKIs (Fig. 1a) requires
administration of higher doses to obtain optimal VEGFR
blockade and efficacy; however, higher doses are in turn
associated with increased blockade of non-VEGF kinases
due to low selectivity (Fig. 1b), leading to toxicities that
often require dose reductions or interruptions. The off-
target effects of multitargeted TKIs have also limited
their use in combination regimens due to overlapping
toxicities with chemotherapeutic drugs. These limitations
of multitargeted TKIs have led to the development of
more selective and potent anti-VEGFR TKIs (Table 1),
with the objective of providing improved antitumor
activity with fewer off-target toxicities at therapeutic
doses.
Second-Generation VEGFR TKIs
Tivozanib
Tivozanib (AV-951) is an extremely potent and selective
oral pan-VEGFR TKI with picomolar potency to each of
the three VEGFRs (VEGFR-1, 0.21 nM; VEGFR-2, 0.16
n M ;V E G F R - 3 ,0 . 2 4n M ) ,w h i c hr e s u l t si nah i g h
selectivity for the VEGFRs relative to other kinases [18,
Fig. 1 Relative VEGFR potencies a and selectivities b of multi-
targeted and VEGFR TKIs [19, 23, 25￿, 49, 64–66]. Potency toward
the VEGFR-1, -2, and -3 kinases is expressed as IC50 values.
Selectivity was calculated as the ration of mean potency toward
VEGFR-1, -2, and -3 versus the next most potent off-target kinase
(indicated in brackets) for each agent; selectivity <1 indicates a higher
potency for the off-target kinase versus VEGF kinase. c-kit stem cell
factor receptor; IC50 half-maximal inhibitory concentration; PDGFR
platelet-derived growth factor receptor; TKI tyrosine kinase inhibitor;
VEGFR vascular endothelial growth factor receptor
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involving patients with locally advanced or metastatic
RCC (83% of whom had clear cell RCC, and 73% of
whom had undergone nephrectomy) evaluated 16 weeks of
open-label treatment with tivozanib 1.5 mg/day, after
which patients who had <25% tumor change were
randomized to 12 weeks of treatment with tivozanib or
placebo. Preliminary results indicate that among all treated
patients (N=272), tivozanib was associated with an ORR of
27% and a median PFS of 11.8 months. Among those with
clear cell RCC who had undergone nephrectomy (n=176),
the ORR was 32% and the median PFS was 14.8 months
[20￿]. Among those patients randomized to double-blind
treatment, median PFS was longer among those randomized
to receive tivozanib (n=58; 12.1 months) compared with
placebo (n=53; 6.3 months), with a significantly greater
proportion of patients progression free after 12 weeks of
treatment on the tivozanib arm (P=0.003) [21￿]. Of the 29
patients with progressive disease while on placebo, 26
patients crossed back to open-label tivozanib and 24
experienced response or stable disease. The most common
adverse events observed in >20% (any grade) were
hypertension (50%) and dysphonia (22%); the incidences
of gastrointestinal events, fatigue, and hand-foot syndrome
were low. Grade 3 adverse events included hypertension
(8%) and asthenia (2%); an additional 1% of patients
experienced grade 4 hypertension [20￿]. As observed with
agents approved in RCC, response to tivozanib and median
PFS were higher among patients experiencing hypertension
during treatment compared with those that did not [22]. An
ongoing open-label phase 3 trial (TIVO-1) is comparing
tivozanib versus sorafenib in treatment-naive or cytokine-
pretreated patients with advanced clear cell RCC who have
undergone a nephrectomy (ClinicalTrials.gov identifier:
NCT01030783).
Preliminary results from an ongoing phase 1 study [23]
evaluated the combination of tivozanib with temsirolimus, a
mammalian target of rapamycin (mTOR) inhibitor, in patients
with metastatic RCC. The combination was well tolerated at
full doses of each agent (tivozanib 1.5 mg/day and temsir-
olimus 25 mg/week), with no dose-limiting toxicities ob-
served and no evidence of pharmacokinetic interaction
between tivozanib and temsirolimus. Clinical activity was
encouraging, with 2 of 16 patients achieving confirmed partial
responses and 8 patients achieving stable disease for
>10 weeks as of the cutoff date. Grade 3 adverse events
included thrombocytopenia, fatigue/asthenia, hypertension,
and rash, each of which was reported by 1 patient (6%)
[23]. Tivozanib is the first TKI to be safely combined with an
mTOR inhibitor at full dose and schedule of both agents. A
study evaluating the combination of tivozanib with everolimus
is ongoing (ClinicalTrials.gov identifier: NCT01058655).
Tivozanib is also currently being evaluated in patients
withothercancertypes,includinga phase1studyoftivozanib
monotherapy in patients with NSCLC (ClinicalTrials.gov
identifier: NCT00826878), a phase 1 study of tivozanib in
combination with paclitaxel in patients with advanced or
metastatic breast cancer (ClinicalTrials.gov identifier:
NCT00717340), and a phase 1 study of tivozanib in
combination with FOLFOX6 in patients with advanced
colorectal and other gastrointestinal cancers (ClinicalTrials.
gov identifier: NCT00660153).
Table 1 Clinical activity and tolerability of monotherapy with second-generation VEGFR TKIs in RCC
Agent Study design Activity Grade ≥3 adverse events (active treatment arms)
Axitinib Phase 2, single-arm, 52 patients
with clear cell mRCC [25￿]
ORR 44%; TTP 15.7 months;
OS 29.9 months
Hypertension (8%), diarrhea (5%), fatigue (4%),
anorexia (1%), limb pain (2%), arthralgia (1%),
myalgia (1%), stomatitis (1%)
Phase 2, single-arm, 62 patients with
sorafenib-refractory clear cell mRCC [26￿]
ORR 23%; PFS 7.4 months;
OS 13.6 months
Hand-foot syndrome (16%), fatigue (16%),
hypertension (16%), dyspnea (15%), diarrhea
(15%), dehydration (8%), hypotension (7%)
Tivozanib Phase 2, randomized discontinuation
study of 272 patients with locally
advanced or mRCC (all histologies) [20￿]
ORR 27%; PFS 11.8 months Hypertension (9%), asthenia (2%)
Randomized, placebo-controlled
phase (n=111) [21￿]
Tivozanib: PFS 12.1 months
Placebo: PFS 6.3 months
Cediranib Phase 2, randomized, placebo-
controlled; 71 patients with
advanced RCC [37]
Cediranib: tumor size −20%;
ORR 34%; PFS 12.1 months
Fatigue (19%), hypertension (19%),
diarrhea (13%)
Placebo: tumor size +19%;
PFS 2.7 months
mRCC metastatic renal cell carcinoma; ORR objective response rate; TTP time to progression; OS overall survival; PFS progression-free survival;
RCC renal cell carcinoma; TKI tyrosine kinase inhibitor; VEGFR vascular endothelial growth factor receptor.
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Axitinib (AG-013736) is a potent small-molecule inhibitor
of all known VEGFRs, with lower potency against PDGFR
and c-kit [24]. In a phase 2 study [25￿] of 52 patients with
metastatic clear cell RCC (94% of whom had undergone
nephrectomy), axitinib was initiated at 5 mg twice daily.
Dose escalation was possible in 6 patients (12%), and dose
reductions were required in 42% of patients because of
grade 2 (13%) and grade 3 (29%) adverse events. Axitinib
was associated with an ORR of 44% (2 complete and
21 partial responses), with a median duration of response of
23 months. Median time to progression was 15.7 months,
and median OS was 29.9 months; PFS was not reported.
Adverse events observed in >20% of patients were diarrhea
(60%), hypertension (58%), fatigue (52%), nausea (44%),
dysphonia (37%), anorexia (35%), dry skin (33%), weight
loss (27%), dyspepsia (23%), and vomiting (21%). Grade 3
or 4 treatment-related adverse events included hypertension
(15%), diarrhea (5%), and fatigue (4%). Hypertension of
any grade was reported in 30 (58%) patients but resolved
with antihypertensive treatment in all but 8 patients (7 of
whom had a previous history of hypertension) [25￿]. In a
second phase 2 study [26￿] involving 62 patients with
sorafenib-refractory metastatic RCC (95% with clear cell
histology, all had undergone nephrectomy), axitinib 5 mg
twice daily provided an ORR of 23%, with a median
duration of response of 17.5 months. An additional 21
(34%) patients had stable disease. Median PFS was
7.4 months, and median OS was 13.6 months. The most
common adverse events were fatigue (77%), diarrhea
(61%), anorexia (48%), hypertension (45%), nausea
(44%), and dyspnea (39%). Hand-foot syndrome (35%)
and mucositis (34%) were also common. Grade 3 or 4
adverse events included hand-foot syndrome (16%), fatigue
(16%), hypertension (16%), dyspnea (15%), diarrhea
(15%),dehydration(8%),andhypotension(7%).Thereappears
to be an association between hypertension and efficacy of
axitinib: a pooled analysis [27] of phase 2 data demonstrated
that median OS for patients with at least one diastolic blood
pressure measurement ≥90 mm Hg (n=59) during axitinib
therapy was 130 weeks compared with 42 weeks for patients
without elevated diastolic blood pressure (n=50; P<0.01).
No apparent relationship between drug concentrations and
maximum diastolic blood pressure was observed. Axitinib is
currently being compared with sorafenib predominantly in the
second-line setting in two phase 3 studies in patients with
treatment refractory metastatic clear cell RCC (ClinicalTrials.
gov identifiers: NCT00678392 and NCT00920816).
Axitinib has also demonstrated efficacy in patients with
several other cancer types. As monotherapy, axitinib
showed activity against thyroid cancers in a phase 2 study
(n=60) [28￿], yielding an ORR of 30% and a median PFS
of 18.1 months. In a phase 2 study [29] of 32 patients with
stage IV melanoma, treatment with axitinib resulted in an
ORR of 16%, a median PFS of 2.3 months, and a median
OS of 13.0 months in patients with diastolic blood pressure
≥90 mm Hg and 6.2 months for those without. In advanced
non–small cell lung cancer (NSCLC), a disease control rate
of 41%, median PFS of 4.9 months, and median OS of
14.8 months were achieved with axitinib in a phase 2 study
(n=32) [30￿].
Axitinib has also demonstrated activity in advanced
NSCLC and other solid tumors in combination with chemo-
therapy in a phase 1 study (n=47) [31]: ORR was 29% when
combined with paclitaxel plus carboplatin (platinum-naive
and taxane-naive patients) and 26% when combined with
gemcitabine plus cisplatin (pretreated patients). In a random-
ized phase 2 study (n=168) [32], axitinib combined with
docetaxel showed promising activity in metastatic breast
cancer, with a median time to progression of 8.2 months with
the combination versus 7 months with docetaxel alone (P=
0.052) and an ORR of 40% with the combination versus
23% with docetaxel alone (P=0.038). A phase 1 study [33]
assessed the combination of axitinib with bevacizumab, a
monoclonal antibody to the VEGF ligand, plus chemother-
apy (FOLFOX) compared with axitinib plus chemotherapy
(FOLFOX or FOLFIRI) in 30 patients with metastatic
colorectal cancer and other solid tumors. Responses were
observed with all treatment combinations, although patient
numbers were too small for statistical comparisons [33]. In
contrast to the other cancer types evaluated, the addition of
axitinib to gemcitabine in pancreatic cancer has demonstrat-
ed only small nonsignificant clinical improvements com-
pared with gemcitabine alone in phase 2 (n=103) [34]a n d
phase 3 (n=632) [35] studies, and is not recommended for
further evaluation.
Across all cancer types, the most common adverse
events observed with axitinib treatment were hypertension,
gastrointestinal events, fatigue, anorexia, and hematologic
abnormalities [25￿, 26￿, 28￿, 29, 30￿, 31–35]. Notably, in a
phase 1 study [33] of patients with colorectal and other
cancers, the incidence of hypertension was 81% among
patients receiving axitinib plus bevacizumab and chemo-
therapy versus 27% among those receiving axitinib plus
chemotherapy without bevacizumab.
Several additional clinical studies are ongoing to
evaluate axitinib therapy in patients with the above cancers
as well as advanced gastric cancers, soft tissue sarcomas,
and acute myeloid leukemia or myelodysplastic syndrome
(ClinicalTrials.gov).
Cediranib
Cediranib (AZD2171) is an oral VEGFR TKI that has
affinity for the VEGFRs, c-kit, PDGFRβ, fibroblast growth
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a phase 2 study [37], 71 patients with advanced or
metastatic RCC were randomized to 12 weeks of treatment
with cediranib 45 mg/day (n=53) or placebo (n=18). The
mean change in tumor size from baseline was significantly
greater among patients randomized to cediranib (20%
reduction) versus placebo (19% increase; P<0.0001), with
partial responses observed in 34% of patients in the
cediranib arm. Median PFS was also significantly greater
with cediranib (12.1 months) versus placebo (2.7 months; P
=0.017). Common grade 3 or 4 adverse events included
fatigue (19%), hypertension (19%), and diarrhea (13%); 58
(87%) patients required a dose reduction or interruption due
to toxicities [37]. Preliminary results from another phase 2
study [38] of 43 patients with metastatic RCC have shown
partial responses in 38% of patients and a median PFS of
8.7 months during treatment with cediranib 45 mg/day.
Treatment-related grade 3 or 4 adverse events included
hypertension (30%), fatigue (26%), joint pain (12%),
dyspnea (12%), and abdominal pain (5%).
Cediranib monotherapy has also demonstrated promising
efficacy in patients with a range of other cancers. In an
open-label exploratory study [39] involving 19 patients
with recurrent or metastatic head and neck cancer or
NSCLC, 6 (35%) patients showed a reduction in tumor
metabolic activity of ≥25% (assessed by fluorodeoxyglu-
cose positron emission tomography) after 71 days of
treatment with cediranib 30 mg/day. In a phase 2 study
[40] of patients with recurrent glioblastoma, treatment with
cediranib 45 mg/day resulted in radiographic partial
response in 27% to 57% of patients, depending upon
assessment methodology; the median PFS was 3.8 months,
and median OS was 7.5 months. In another phase 2 study
[41] involving 47 patients with recurrent epithelial ovarian,
fallopian tube, or peritoneal cancer, treatment with cedir-
anib provided clinical benefit (response or stable disease) in
14 (30%) patients; the original dose of cediranib was
45 mg/day, but was subsequently reduced to 30 mg/day
because of toxicities in the first 11 patients (primarily
fatigue [52%] and diarrhea [31%]). Preliminary results from
a phase 2 study [42] in men with castration-resistant
prostate cancer that had progressed on docetaxel therapy
showed evidence of antitumor activity with cediranib
20 mg/day, with 19 of 34 patients achieving tumor
regression, including 6 with partial responses.
Cediranib has also been investigated in a number of
combination regimens in breast, colorectal, NSCLC, and
small cell lung cancer. Studies of cediranib in combination
with chemotherapy in patients with advanced lung cancers
have produced inconsistent results, which typically did not
demonstrate significant improvement with the addition of
cediranib [43–46]. The ORR for patients with NSCLC
ranged from 16% to 38% with cediranib and 16% to 18%
without; median PFS ranged from 5.6 to 6.3 months with
cediranib to 4.5 to 5.0 months without [43–45]. Further,
addition of cediranib was associated with dose reduction/
interruption and/or discontinuation due to toxicity in a
majority of patients from each study [43, 44, 46]. Similar
results have been observed for cediranib 20 mg/day in
combination with FOLFOX chemotherapy versus bevaci-
zumab plus chemotherapy as first-line therapy in patients
with metastatic colorectal cancer [47], and for cediranib
45 mg/day in combination with fulvestrant (selective
estrogen-receptor antagonist) in women with hormone-
sensitive metastatic breast cancer [48].
Across cancer types, study results have shown that,
although generally effective, cediranib at 45 mg/day was not
well tolerated [41, 45, 46, 48], with one study in NSCLC
indicating that the lower dose of 30 mg/day cediranib in
combination with chemotherapy was not well tolerated either
[44]. Overall, the most frequently reported toxicities with
cediranib include hematologic abnormalities, fatigue, hyper-
tension, anorexia, dysphonia, gastrointestinal events, and
hepatobiliary abnormalities [37–39, 41, 44–46, 48].
Several ongoing clinical trials are evaluating cediranib in
patients with the above cancer types as well as in patients
Table 2 Cross trial comparison of selected “off-target” effects and the rates of dose reduction or dose interruptions with VEGFR TKIs in RCC
All grades (grades 3–4) Sunitinib [62]
(n=375)
Sorafenib [63]
(n=451)
Pazopanib [15￿￿]
(n=290)
Axitinib [25￿]
(n=52)
Tivozanib [20￿]
(n=272)
Adverse events
Mucositis/stomatitis 43% (10%) NA NA 9% (1%) 4% (<1%)
Hand-foot syndrome 21% (5%) 30% (6%) NA NA 4% (<1%)
Rash/desquamation 27% (1%) 40% (1%) NA 6% (0%) 6% (1%)
Fatigue 58% (9%) 37% (6%) 19% (2%) 27% (4%) 8% (2%)
Diarrhea 58% (6%) 43% (2%) 52% (4%) 31% (5%) 12% (2%)
Dose reduction 32% 13% NA 29% 10%
Dose interruption 38% 21% 14% NA 4%
NA not available; RCC renal cell carcinoma; TKI tyrosine kinase inhibitor; VEGFR vascular endothelial growth factor receptor.
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and soft tissue sarcomas (ClinicalTrials.gov).
Other TKIs in Development with VEGFR Affinity
Several other TKIs with anti-VEGFR affinity are also in
various stages of clinical development, although most are
novel multitargeted TKIs. BIBF 1120 is a potent blocker
of VEGFR, PDGFR, and FGFR kinase activity, which
has shown antitumor activity and acceptable tolerability
in preclinical models [49]. Results from a phase 2 study
[50] suggest that maintenance therapy with BIBF 1120 at
2 5 0m gt w i c ed a i l yc o u l dd e l a yd i s e a s ep r o g r e s s i o ni n
ovarian cancer after previous response to chemotherapy
[50]. BMS-690514 is a potent and reversible inhibitor of
VEGFR, EGFR, human epidermal growth factor (HER)-2,
and HER-4 [51]. In a phase 1 study [51]o f3 0p a t i e n t s
with a variety of advanced or metastatic solid tumors,
BMS-690514 at the maximum tolerated dose of 150 mg/
day plus paclitaxel and carboplatin produced partial
responses in 9 (30%) patients. Brivanib (BMS-582664)
is a dual inhibitor of VEGFR-2 and FGFR-1 [52]t h a th a s
shown evidence of activity against hepatocellular cancer
in a phase 2 study (n=96) [53]. Dovitinib (TKI258), an
inhibitor of FGFR, VEGFR, PDGFR, and other tyrosine
kinases, has demonstrated clinical activity and acceptable
toxicity in preliminary reports from a phase 1/2 study
(n=60) in RCC [54] and a phase 1 study (n=19) in
melanoma [55]. Motesanib (AMG 706), an inhibitor of
VEGF, PDGF, and c-kit receptors, has demonstrated
efficacy in combination with paclitaxel and carboplatin
similar to that observed with bevacizumab plus chemo-
therapy in a phase 2 open-label study (n=181) [56]i n
advanced NSCLC. A phase 1b study (n=26) [57]o f
motesanib demonstrated a good tolerability profile when
combined with gemcitabine in the treatment of solid
tumors. Vandetanib (ZD6474), a dual inhibitor of VEGFR
and EGFR tyrosine kinases, has demonstrated efficacy in
NSCLC and medullary thyroid cancer, while negative
results have been observed in phase 2 studies in small cell
lung cancer, metastatic breast cancer, and multiple
myeloma [58]. The feasibility and tolerability of the dual
VEGFR and PDGFR inhibitor telatinib (BAY 57-9352)
has been demonstrated in a phase 2 study [59]i np a t i e n t s
with advanced gastric and gastroesophageal cancers. A
phase 1 study [60] in patients with advanced NSCLC
(n=23) has demonstrated acceptable tolerability with
regorafenib (BAY 73-4506), a multikinase inhibitor of all
three VEGFRs, PDGFR, FGFR, c-kit, and several other
receptors. Vatalanib (PTK787/ZK222584), an inhibitor of
VEGFR-1, -2, and -3, has shown efficacy in stabilizing
metastatic melanoma in a phase 2 study [61]. Studies of
the above agents in a variety of cancer types are currently
planned or ongoing (ClinicalTrials.gov).
Conclusions
Currently available multitargeted agents provide impor-
tant clinical benefits for patients with VEGF-driven
tumors, such as RCC. However, these agents are also
associated with off-target toxicities that limit their
effectiveness. The development of second-generation
VEGFR TKIs with improved potency and selectivity
has the potential to provide more effective and better
tolerated treatment options, enabling rationally designed
combination therapies. Available data from clinical
studies suggest that second-generation TKIs are generally
associated with lower off-target toxicities (Table 2).
Ongoing and future studies will further evaluate the
clinical effectiveness and tolerability of VEGFR TKIs in
a variety of tumor types.
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